ALSO NOTED: Barr challenges Sanofi patents on $1.1B drug; Wockhardt to launch copycat Zoloft;

> Barr Laboratories is challenging Sanofi-Aventis patents on Eloxatin, a colon-cancer drug that Barr wants to copy; Eloxatin posted $1.1 billion in U.S. sales for the 12 months ended in October. Report

> India's Wockhardt got the FDA's nod for its copycat version of Zoloft, or sertraline; the generics maker plans to launch the drug within the next few weeks. Report

> The FDA plans to meet later this month to consider Entereg, a potential constipation drug co-developed by GlaxoSmithKline and Adolor. Report

> Chinese pharma's production value has grown by 20 percent annually over the past decade, according to a new report, which also points out weaknesses in the industry there. Report

> Shares of Isis Pharmaceuticals rocketed up 45 percent after the biotech announced that Genzyme had signed on as a partner to develop the promising cardiovascular drug mipomersen, its flagship product. Report

> Sirtris grabbed some headlines at the JP Morgan gathering in San Francisco with its presentation of positive, early-stage data for its closely watched therapy based on resveratrol, an ingredient in red wine that has been linked to increased longevity. Report

> WuXi's buyout deal has raised questions about scientists' pay scale. Report

And Finally... Forego those french fries and pick up a peach! A new study shows healthy habits could add up to 14 years to your life. Report

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.